AR102120A1 - MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY - Google Patents

MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY

Info

Publication number
AR102120A1
AR102120A1 ARP150103131A ARP150103131A AR102120A1 AR 102120 A1 AR102120 A1 AR 102120A1 AR P150103131 A ARP150103131 A AR P150103131A AR P150103131 A ARP150103131 A AR P150103131A AR 102120 A1 AR102120 A1 AR 102120A1
Authority
AR
Argentina
Prior art keywords
modified
reduced immunogenicity
interfer
nucleic acid
acid molecule
Prior art date
Application number
ARP150103131A
Other languages
Spanish (es)
Inventor
D Martin William
Searls De Groot Anne
Federico Mufarrege Eduardo
Etcheverrigaray Marina
Original Assignee
Univ Nac Del Litoral
Consejo Nac De Investig Científicas Y Técnicas (Conicet)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Del Litoral, Consejo Nac De Investig Científicas Y Técnicas (Conicet) filed Critical Univ Nac Del Litoral
Priority to ARP150103131A priority Critical patent/AR102120A1/en
Publication of AR102120A1 publication Critical patent/AR102120A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente describe un interferón modificado con inmunogenicidad reducida que comprende la sustitución de al menos 3 aminoácidos. Además, se describe una molécula de ácido nucleico que codifica para dicho interferón; una célula de expresión de proteínas recombinantes que comprende dicha molécula de ácido nucleico que codifica para dicho interferón modificado; donde dicha célula de expresión de proteínas recombinantes comprende un plásmido o vector que contiene dicha molécula de ácido nucleico.The present discloses a modified interferon with reduced immunogenicity comprising the substitution of at least 3 amino acids. In addition, a nucleic acid molecule encoding said interferon is described; a recombinant protein expression cell comprising said nucleic acid molecule encoding said modified interferon; wherein said recombinant protein expression cell comprises a plasmid or vector containing said nucleic acid molecule.

ARP150103131A 2015-09-29 2015-09-29 MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY AR102120A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP150103131A AR102120A1 (en) 2015-09-29 2015-09-29 MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP150103131A AR102120A1 (en) 2015-09-29 2015-09-29 MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY

Publications (1)

Publication Number Publication Date
AR102120A1 true AR102120A1 (en) 2017-02-08

Family

ID=58698541

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103131A AR102120A1 (en) 2015-09-29 2015-09-29 MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY

Country Status (1)

Country Link
AR (1) AR102120A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076504A4 (en) * 2019-12-17 2024-04-10 Epivax Inc Modified interferon-alpha-2 having reduced immunogenicity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076504A4 (en) * 2019-12-17 2024-04-10 Epivax Inc Modified interferon-alpha-2 having reduced immunogenicity

Similar Documents

Publication Publication Date Title
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
AU2017335890B2 (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
PH12018501355A1 (en) Rsv f protein mutants
CL2018002825A1 (en) Vrs vaccine
BR112017019625A2 (en) udp-glycosyltransferases
MX2022008508A (en) Enzymes and applications thereof.
BR112016007868A2 (en) epstein-barr virus vaccines
BR112018008766A2 (en) variants, compositions and methods and uses of the reduced factor viii cpg for the treatment of hemostasis disorders
TN2015000085A1 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
BR112014019901A8 (en) RECOMBINANT FACTOR VIII PROTEINS
WO2016107818A8 (en) Compositions and methods for protein glycosylation
CL2013001124A1 (en) Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process.
ES2721309T3 (en) Composition for preparing tagatose and method for preparing tagatose from fructose
BR112016015187A2 (en) A method of inhibiting angiogenesis, or the growth of fusion proteins and their use
EA201401211A1 (en) IMPROVED CHIMOZIN ENZYME OPTIONS
BR112017020308A2 (en) udp-glycosyltransferases
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
WO2016130628A8 (en) Griffithsin mutants
CL2018000164A1 (en) Recombinant vector of the orf virus.
CL2017000200A1 (en) Enhanced host cell to produce proteins
PH12017502323A1 (en) Novel xylanase
BR112016026842A2 (en) preparation comprising factor viii and von willebrand factor peptides
AR102950A1 (en) LIPASE AND POLINUCLEOTIDE VARIANTS CODING THEM
CO2017011431A2 (en) Variant epidermal growth factor receptor fusion proteins iii - mesothelin
BR112021012240A2 (en) Hematopoietic stem cell gene therapy for wiskott-aldrich syndrome